MedTrace Logo

Comparative Urine Proteomic Studies of Overactive Bladder in Humans

NCT01367886 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2015-02-27

Study results available
· View outcomes & findings →

Summary

This study is being done to evaluate the use of a new technology (urine proteomics) - the study of proteins in the urine to identify urine markers of overactive bladder (OAB) from a simple voided urine specimen.

Conditions

Interventions

DRUG

fesoterodine

Fesoterodine 4 mg. tablet by mouth daily for six weeks

Sponsors & Collaborators

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • H. Henry Lai, M.D. · Washington University School of Medicine

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01367886 on ClinicalTrials.gov